10x Genomics Denmark ApS: Financial statements 2022
CVR: 40243224
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
10x Genomics Denmark ApS (CVR 40243224) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK 7,333,851 and a net result of DKK 2,820,214 compared with DKK 39,803,587 the year before. That is a decrease of 85.9% compared with the year before. Equity in the 2022 report amounted to DKK 1,221,922. The solvency ratio was 19.9%. The company had 5 employees in the financial year.
- Gross Profit
- DKK 7,333,851
- Profit/Loss
- DKK 2,820,214
- Equity
- DKK 1,221,922
- Total Assets
- DKK 6,140,477
- Employees
- 5
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | 7.3 mio. | 2.8 mio. | 1.2 mio. | 5 |
| 2021 | - | 52.2 mio. | 39.8 mio. | 38.4 mio. | 2 |
| 2020 | - | -1.6 mio. | -2 mio. | -1.4 mio. | 2 |
| 2019 | - | 552 t. | 245 t. | 625 t. | - |
Official annual report
Keep an eye on 10x Genomics Denmark ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
As of November 18, 2022, Søren Nyboe Jakobsen has stepped down as director of 10x Genomics Denmark ApS.
On November 18, 2022, the company changed its name from Tetramer Shop ApS to 10x Genomics Denmark ApS.
10x Genomics Denmark ApS has published its annual report for 2021. Gross profit came to DKK 52,191,085, and the net result was DKK 39,803,587.
About 10x Genomics Denmark ApS
10x Genomics Denmark ApS is a Danish company of the type Anpartsselskab based in København Ø, founded in 2019. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named Tetramer Shop ApS. The management consists of Adam Samuel Taich and James Sears Bryant. The company is owned by 10x Genomics, Inc.. The company has 2 employees (2026). In 2025, the company reported a gross profit of DKK 3,442,436 and a net result of DKK 154,956 compared with DKK 183,445 the year before. Equity in the 2025 report amounted to DKK 973,740.